Introduction
============

Acute kidney injury (AKI), previously termed acute renal failure, is characterized by a sudden decrease in renal function, primarily described in recent years using the widely accepted 2012 Kidney Disease Improving Global Outcomes (KDIGO) classification based on changes in the serum creatinine (SCr) level and/or urine output.[@b1-cia-12-011] AKI is more frequent in the elderly, and a relationship between AKI incidence and age is evident.[@b2-cia-12-011]--[@b6-cia-12-011] However, few studies have specifically examined AKI in the geriatric population, despite the increasing elderly population and its higher chances of developing AKI.

Despite significant improvements in health care technology in recent years, the mortality of AKI patients remains unacceptably elevated.[@b7-cia-12-011]--[@b9-cia-12-011] One reason for this phenomenon is that the SCr level alone is a relatively late and imprecise biomarker of kidney dysfunction, which may also lead to a delayed diagnosis, especially in the elderly population.[@b10-cia-12-011],[@b11-cia-12-011]

Clinical studies have shown that a timely nephrology consultation (NC) could potentially have many benefits such as allowing earlier identification and modification of AKI patients' outcomes. For example, Mehta et al concluded that a delayed NC was associated with increased mortality among dialyzed and nondialyzed patients in the intensive care unit (ICU).[@b12-cia-12-011] Recent studies have also indicated that an early NC may improve hospital-acquired AKI prognosis,[@b12-cia-12-011]--[@b16-cia-12-011] although few studies have examined the effect of an early NC on outcomes in very elderly patients (≥75 years) or diagnosing AKI using KDIGO criteria.

The aims of this study were to compare the clinical and laboratory characteristics of elderly AKI patients evaluated and not evaluated by nephrologists and to generate a hypothesis of the relationship between the timing of the NC and 90-day outcomes.

Study population and methods
============================

This was a retrospective cohort study. All elderly patients (≥75 years) who were admitted to the Geriatric Department of the Chinese People's Liberation Army (PLA) General Hospital between January 2007 and December 2015 were evaluated for AKI during their hospital stay. The study design was approved by the Clinical Ethics Committee of the Chinese PLA General Hospital, and each participant provided written informed consent. All AKI patients were followed up for 90 days after AKI diagnosis or until death.

Clinical data were noted, including the demographic profile (age, gender, and body mass index) and comorbidities (history of hypertension, coronary disease, chronic obstructive pulmonary disease \[COPD\], and diabetes mellitus), time of AKI diagnosis, etiology of AKI (induced by infection, hypovolemia, cardiovascular events, nephrotoxic drugs, surgery, or uncertain causes), need for dialysis, need for mechanical ventilation (MV), urine output, and mean aortic pressure. Other laboratory data evaluated included baseline levels of SCr, SCr at AKI diagnosis, peak SCr, blood urea nitrogen (BUN), uric acid, serum prealbumin, albumin, kalemia, serum calcium, serum magnesium, serum phosphate, and hemoglobin.

AKI was diagnosed exclusively based on SCr levels, that is, an SCr increase ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or an increase to ≥1.5-fold above the baseline value within the prior 7 days.[@b1-cia-12-011] The KDIGO criteria were used. AKI severity was scored according to the difference between the SCr baseline and peak values, using the KDIGO staging criteria: stage 1, an increase ≥26.5 µmol/L, or an increase ≥1.5- to 1.9-fold above the baseline value; stage 2, an increase to ≥2- to 2.9-fold above the baseline value; and stage 3, an increase to ≥3-fold above the baseline value, an increase to ≥353.6 µmol/L, or initiation of renal replacement therapy. Urine output was not available in the cohort, and the KDIGO urine output criteria could not be applied.

The baseline SCr level was the most recent stable measure obtained 3 months prior to hospital admission for AKI.[@b5-cia-12-011] The peak SCr was the highest SCr level reached in the episode. Estimated glomerular filtration rates (eGFRs) were calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method.[@b17-cia-12-011] Oliguria was defined as urinary output \<400 mL/24 h.

The exclusion criteria were age \<75 years, patients with a history of CKD of any stage,[@b18-cia-12-011] hospital stay of \<48 h, those who had no SCr or only one SCr examination, those with missing or incomplete medical history, and those with early death in \<48 h after admission. Females were also excluded, because fewer females were treated than males during the study period.

All elderly AKI patients were divided into two groups: those evaluated and not evaluated by nephrologists. Thereafter, AKI patients evaluated by nephrologists were further divided into two subgroups (early and delayed consultation) based on the time to consultation from the day of laboratory diagnosis of AKI. An early NC was defined as ≤48 h and a delayed NC was defined as \>48 h.

The primary outcome was 90-day mortality. Clinical and laboratory characteristics were also recorded.

Statistical analysis
--------------------

Continuous variables are presented as the mean ± standard deviations, or medians (25%--75% interquartile range), depending on the variable distribution. Discrete variables are presented as counts or percentages. Between-group comparisons were performed using Student's *t*-test or the Mann--Whitney *U*-test. Correlations between potential factors were assessed using Pearson's chi-squared or Fisher's exact test. Multivariable logistic regression models were constructed with forward variable selection, with the exit criterion set at *P*\<0.25. A *P*-value \<0.05 was considered to reflect statistical significance. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) Version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

Among 1,711 study patients, 668 (39%) developed AKI. Only 45 patients were excluded, resulting in 623 AKI patients suitable for analysis. The study flowchart is presented in [Figure 1](#f1-cia-12-011){ref-type="fig"}. The median age of the cohort was 87 years. The median baseline SCr level was 74 µmol/L, and baseline eGFR was 78.4 mL/min/1.73 m^2^. Using the KDIGO criteria, 294 patients (47.2%) had stage 1 AKI, 157 (25.2%) had stage 2 AKI, and 172 (27.6%) had stage 3 AKI. Of the 623 patients, 78.2% had coronary disease, 73.8% had hypertension, 70.3% had COPD, and 35.8% had diabetes mellitus. An NC was performed in 26% (162/623) of AKI patients and occurred 2 (1--4) days after the day of AKI diagnosis. Most patients referred to nephrologists were subjected to an early NC (63.6%). The overall 90-day mortality was 33.2% (207/623), and dialysis was required in only 1.4% (9/623) of patients.

NC
--

As shown in [Table 1](#t1-cia-12-011){ref-type="table"}, NC patients were older (median age: 88 vs 87 years, *P*=0.115), and the majority of these patients had COPD (79% vs 67.2%, *P*=0.005). Of the 162 (26%) patients referred to nephrologists, AKI diagnosis occurred after 2 days (1--5 days), compared to 4 days (2--7 days) for patients not evaluated by nephrologists (*P*=0.001). The median SCr level (70 vs 75 µmol/L, *P*=0.010) and eGFR (80.1 vs 78 mL/min/1.73 m^2^, *P*=0.032) at baseline were significantly different between the two groups.

As shown in [Table 1](#t1-cia-12-011){ref-type="table"}, patients evaluated by nephrologists presented higher mortality rate (46.9% vs 28.4%, *P*\<0.001), with more patients in KDIGO stage 3, and fewer patients in stage 1 (51.9% vs 19.1%, 22.8% vs 55.7%; *P*\<0.001). Oliguria (9.9% vs 4.1%, *P*=0.006), dialysis (5.6% vs 0%, *P*\<0.001), requiring MV (51.9% vs 31.9%, *P*\<0.001), anemia (109±23 vs 113±22 g/L, *P*=0.013), a lower prealbumin level (168 vs 186 g/L, *P*=0.011), and hypoalbuminemia (33±5.2 vs 34.8±5.5 g/L, *P*=0.001) were more frequent among patients referred to nephrologists. NC patients had significantly higher uric acid (399.2 vs 360 µmol/L, *P*=0.005), kalemia (4.3 vs 4.1 mmol/L, *P*=0.035), and phosphate levels (1.3 vs 1.2 mmol/L, *P*=0.031). As expected, patients evaluated by nephrologists had higher SCr, BUN, and peak SCr levels at the time of AKI diagnosis (all *P*\<0.001), and the presence or absence of an NC was associated with 90-day mortality ([Figure 2](#f2-cia-12-011){ref-type="fig"}).

Multivariate logistic regression analysis revealed that an NC was significantly associated with a higher prevalence of preexisting COPD (odds ratio \[OR\] =1.794; 95% confidence interval \[CI\]: 1.118--2.879; *P*=0.015), AKI diagnosis time (OR =0.888; 95% CI: 0.812--0.972; *P*=0.010), peak SCr level (OR =1.006; 95% CI: 1.003--1.008; *P*\<0.001), BUN level (OR =1.022; 95% CI: 1.002--1.043; *P*=0.033), AKI stage (OR =1.472; 95% CI: 1.021--2.122; *P*=0.038), and mortality (OR =0.531; 95% CI: 0.303--0.931; *P*=0.027) ([Table 2](#t2-cia-12-011){ref-type="table"}).

NC timing -- factors associated with a delayed NC
-------------------------------------------------

Several baseline differences were noted between the early and delayed consultation groups ([Table 3](#t3-cia-12-011){ref-type="table"}). Of the 59 (35.6%) patients with delayed consultation, AKI diagnosis occurred after 2 days (2--7 days), while the median time to consultation was 4 days (3--8 days). Delayed NC patients were more likely to be older (median age: 89 vs 88 years, *P*=0.207) and to have a lower median eGFR (78.6 vs 81.4 mL/min/1.73 m^2^, *P*=0.233) than the early NC group. They had higher peak SCr (227 vs 183 µmol/L, *P*=0.180), lower uric acid (361.7 vs 419 µmol/L, *P*=0.004), lower kalemia (4.1 vs 4.4 mmol/L, *P*=0.140), and lower phosphate (1.2 vs 1.3 mmol/L, *P*=0.031) levels at the time of AKI diagnosis. Accordingly, the prevalence of oliguria was significantly lower in the delayed NC group (1.7% vs 14.6%, *P*=0.008).

Multivariate logistic regression analysis revealed that a delayed NC was significantly associated with AKI diagnosis time (OR =1.269; 95% CI: 1.078--1.495; *P*=0.004), oliguria (OR =0.116; 95% CI: 0.014--0.952; *P*=0.045), uric acid level (OR =0.996; 95% CI: 0.994--0.999; *P*=0.009), and a more severe AKI stage (OR =3.365; 95% CI: 1.297--8.733; *P*=0.013) ([Table 4](#t4-cia-12-011){ref-type="table"}).

Influence of a delayed NC on patient outcomes
---------------------------------------------

As shown in [Table 3](#t3-cia-12-011){ref-type="table"}, more patients were classified as KDIGO stage 3 and fewer patients were classified as stage 1 and stage 2 (57.6% vs 48.5%, 18.6% vs 25.2%, 23.7% vs 26.2%; *P*=0.238). Dialysis was necessary in 5.1% of the delayed group, compared to 5.8% of the early group (*P*=1.000). Surprisingly, delayed consultation was not associated with increased mortality (50.8% vs 44.7%, *P*=0.448) ([Figure 3](#f3-cia-12-011){ref-type="fig"}).

Discussion
==========

It is widely recognized that the timing of an NC is associated with AKI patient outcomes. However, few studies have specifically examined this important topic with regard to the very elderly population. This analysis was restricted to patients who developed AKI, compared to the clinical and laboratory characteristics of patients evaluated and not evaluated by nephrologists, and generated a hypothesis regarding the relationship between the timing of the NC and short-term outcomes. In this observational study, 39% of patients developed AKI, and fewer patients (26%) were evaluated by nephrologists. These patients presented higher mortality than those not evaluated, most likely due to their more severe illness characteristics (more patients with oliguria, greater need for dialysis, higher SCr and BUN levels, and more stage 3 patients).

In the present study, 59 of the NCs (36.4%) were delayed (\>48 h), and a delayed consultation was not associated with increased mortality. If this association is valid, it can be inferred that consultation timing itself is not responsible for the decreased mortality risk in elderly AKI patients.

Two recently published studies have evaluated the association between the timing of the NC and patient outcomes.[@b13-cia-12-011],[@b19-cia-12-011] The retrospective observational study by Ponce et al enrolled 148 AKI patients (Acute Kidney Injury Network criteria) treated in the ICU,[@b13-cia-12-011] of whom only 77 were evaluated by nephrologists. Patients in the early NC group had a mean SCr level of 6.6±1.8 mg/dL, compared to a mean SCr level of 4.2±2.4 mg/dL in the delayed group. A delayed NC, using a 48 h interval, was associated with increased mortality after adjustment for multivariable analysis. In a study by Costa e Silva et al,[@b19-cia-12-011] which was a prospective observational study including 366 critically ill AKI patients (RIFLE \[Risk, Injury, Failure, Loss and End-stage Kidney Disease\] criteria), 31.4% (155/366) of patients underwent dialysis, and hospital mortality occurred in 67.8% (248/366). The authors also reported that delayed NC was associated with higher mortality and increased dialysis dependence rates at hospital discharge.

There are several potential reasons why only 26% of the AKI patients were evaluated by nephrologists. One explanation may be the definition of AKI, which is neither uniformly known nor accepted in the non-nephrologic community.[@b15-cia-12-011] Although the KDIGO criteria provide a unique basis for epidemiologic and interventional outcome studies and suggest increasing SCr and urine volume monitoring in patients with a high risk for AKI, these criteria are not commonly used in the clinical setting. Moreover, the SCr level has a nonlinear relationship with the eGFR and requires time to accumulate, thus contributing to delays in the detection of important changes in kidney function. According to the KDIGO criteria, the 48 h window for diagnosis does enhance the sensitivity for earlier diagnosis relative to the 7-day window because if the SCr level significantly increases within 48 h, it is more likely to attract the attention of clinicians. In contrast, if the patient's SCr level increases to 1.5 times the baseline value in 7 days, clinicians may not be aware of AKI occurrence due to the "normal SCr" level, especially among elder people with lower baseline SCr levels. The results also confirmed that the AKI diagnosis time was 2 days in the NC group, compared to 4 days in the group without consultation. Finally, no universal definition for NC timing exists for AKI patients. Elderly patients often had many comorbidities, thus increasing the complexity of medical care and possibly increasing the time required to make treatment decisions.

Several other reasons may explain why early consultation did not improve patient outcomes. First, the study excluded patients with CKD. As CKD is a potent risk factor for mortality, excluding patients with CKD in this analysis may have potentially underestimated the impact of an early NC on survival. Second, although these elderly patients were treated in non-ICU wards, they had close monitoring and timely treatment by practitioners and had reduced the short-term mortality to a certain extent. In addition, of the 163 stage 3 AKI patients, only nine patients required dialysis during follow-up, and nine were evaluated by nephrologists. Decisions about dialysis initiation in very elderly AKI patients are influenced by several factors: AKI severity, blood vessel volume, electrolyte and acid--base status, urine output, hemodynamics, nutritional status, and attending physicians' preferences. An important issue in the present study is that dialysis cannot be initiated without an NC because in the hospital, the nephrologist is the only professional who initiates dialysis; so if the patient is not evaluated by a nephrologist, they are not treated with dialysis.

Limitations
===========

The present study had some potential weaknesses. First, it is a one-center retrospective study, and some potentially important variables were not included, such as the Acute Physiologic and Chronic Health Evaluation II score and the sequential organ failure assessment score, which can also predict AKI patient outcomes. Second, data from a hospital catering to the elderly were analyzed, and because most patients were male and fewer females were treated in the hospital, females were excluded from the study. Thus, biased results are unavoidable. Third, the definition of AKI in this study was based on SCr levels. Urine output criteria were not used because these data were incomplete. Fourth, the follow-up duration was short. The study also did not explore the effects of an NC on kidney outcome.

Conclusion
==========

In summary, among very elderly patients with AKI, an NC was associated with higher severity of disease (ie, higher peak SCr levels, BUN levels, and AKI stage). As expected, mortality significantly differed between patients who underwent a consultation and those who did not receive a consultation. Fewer AKI patients had a delayed NC (median of 4 days); however, a delayed NC may not be associated with increased short-term mortality.
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![Flowchart of patients included and excluded in the study.\
**Abbreviations:** AKI, acute kidney injury; CKD, chronic kidney disease; SCr, serum creatinine.](cia-12-011Fig1){#f1-cia-12-011}

![Kaplan--Meier survival curves for 90-day mortality of AKI in patients with and without a nephrology consultation (log-rank test: *P*\<0.001).\
**Abbreviation:** AKI, acute kidney injury.](cia-12-011Fig2){#f2-cia-12-011}

![Kaplan--Meier survival curves for 90-day mortality in patients with early and delayed nephrology consultations (log-rank test: *P*=0.876).](cia-12-011Fig3){#f3-cia-12-011}

###### 

Comparisons of the clinical characteristics between elderly AKI patients with and without an NC

  ----------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                   AKI patients\          NC\                    No NC\                 *P*-value
                                                    (n=623)                (n=162)                (n=461)                
  ------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Age (years)                                       87 (84--91)            88 (84--91)            87 (84--91)            0.115

  BMI (kg/m^2^)                                     23.0±3.1               23.0±2.9               23.0±3.2               0.658

  Comorbidity                                                                                                            

   Coronary disease                                 487 (78.2)             129 (79.6)             358 (77.7)             0.601

   Hypertension                                     460 (73.8)             121 (74.7)             339 (73.5)             0.773

   COPD                                             438 (70.3)             128 (79)               310 (67.2)             0.005

   Diabetes                                         223 (35.8)             57 (35.2)              166 (36.0)             0.851

  Baseline SCr (µmol/L)                             74.0 (62.0--84.0)      70.0 (60.0--81.3)      75.0 (63.0--84.5)      0.010

  Baseline eGFR (mL/min/1.73 m^2^)                  78.4 (71.3--84.9)      80.1 (72.7--85.9)      78.0 (70.6--84.7)      0.032

  Etiology of AKI                                                                                                        

   Infections                                       247 (39.6)             67 (41.4)              180 (39.0)             0.605

   Hypovolemia                                      148 (23.8)             32 (19.8)              116 (25.2)             0.164

   Cardiovascular events                            99 (15.9)              29 (17.9)              70 (15.2)              0.416

   Nephrotoxicity                                   75 (12)                19 (11.7)              56 (12.1)              0.888

   Surgery                                          44 (7.1)               11 (6.8)               33 (7.2)               0.875

   Others                                           10 (1.6)               4 (2.5)                6 (1.3)                0.513

  AKI diagnosis time (days)                         2.0 (2.0--7.0)         2.0 (1.0--5.0)         4.0 (2.0--7.0)         0.001

  Parameter at the time of AKI diagnosis                                                                                 

   MAP (mmHg)                                       78±14                  79±13                  78±15                  0.977

   Oliguria                                         35 (5.6)               16 (9.9)               19 (4.1)               0.006

   Dialysis                                         9 (1.4)                9 (5.6)                0                      \<0.001

   MV                                               231 (37.1)             84 (51.9)              147 (31.9)             \<0.001

  Laboratory results at the time of AKI diagnosis                                                                        

   SCr (µmol/L)                                     132.0 (118.2--147.0)   138.0 (127.2--160.5)   128.1 (116.2--143.6)   \<0.001

   Peak SCr (µmol/L)                                144.0 (124.8--204.0)   206.5 (143.3--353.7)   137.8 (121.2--173.3)   \<0.001

   BUN (mmol/L)                                     12.8 (8.9--21.3)       16.7 (10.7--26.8)      11.8 (8.4--20.1)       \<0.001

   Uric acid (µmol/L)                               367.0 (293.7--471.0)   399.2 (312.9--506.7)   360.0 (285.0--457.5)   0.005

   Prealbumin (g/L)                                 181 (139--234)         168 (125--227)         186 (143--239)         0.011

   Albumin (g/L)                                    34.3±5.5               33.0±5.2               34.8±5.5               0.001

   Kalemia (mmol/L)                                 4.1 (3.8--4.7)         4.3 (3.8--4.9)         4.1 (3.8--4.6)         0.035

   Magnesium (mmol/L)                               0.9 (0.8--1.0)         0.9 (0.8--1.0)         0.9 (0.8--1.0)         0.972

   Calcium (mmol/L)                                 2.2 (2.1--2.3)         2.2 (2.0--2.3)         2.2 (2.1--2.4)         0.428

   Phosphate (mmol/L)                               1.2 (1.0--1.4)         1.3 (1.0--1.6)         1.2 (0.9--1.4)         0.031

   Hemoglobin (g/L)                                 112±23                 109±23                 113±22                 0.013

  AKI stage                                                                                                              \<0.001

   1                                                294 (47.2)             37 (22.8)              257 (55.7)             

   2                                                157 (25.2)             41 (25.3)              116 (25.2)             

   3                                                172 (27.6)             84 (51.9)              88 (19.1)              

  Mortality rate                                    207 (33.2)             76 (46.9)              131 (28.4)             \<0.001
  ----------------------------------------------------------------------------------------------------------------------------------

**Notes:** Values are n (%), mean ± SD or median (interquartile range). 1 mmHg =0.133 kPa.

**Abbreviations:** AKI, acute kidney injury; NC, nephrology consultation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; MAP, mean aortic pressure (1 mmHg =0.133 kPa); MV, mechanical ventilation; BUN, blood urea nitrogen; SD, standard deviation.

###### 

Associations (with *P*\<0.25) between AKI patients characteristics and NC

  Risk factors         OR      95% CI         *P*-value
  -------------------- ------- -------------- -----------
  Presence of COPD     1.794   1.118--2.879   0.015
  AKI diagnosis time   0.888   0.812--0.972   0.010
  Peak SCr level       1.006   1.003--1.008   \<0.001
  BUN level            1.022   1.002--1.043   0.033
  AKI stage            1.472   1.021--2.122   0.038
  Mortality            0.531   0.303--0.931   0.027

**Abbreviations:** AKI, acute kidney injury; NC, nephrology consultation; SCr, serum creatinine; BUN, blood urea nitrogen; CI, confidence interval; OR, odds ratio.

###### 

AKI patients characteristics according to early and delayed NC

  ----------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                   NC patients\           Delayed NC\            Early NC\              *P*-value
                                                    (n=162)                (n=59)                 (n=103)                
  ------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Age (years)                                       88.0 (84.0--91.0)      89.0 (85.0--91.0)      88.0 (84.0--91.0)      0.207

  BMI (kg/m^2^)                                     23.0±2.9               22.8±3.0               23.0±2.9               0.474

  Comorbidity                                                                                                            

   Coronary disease                                 129 (79.6)             47 (79.7)              82 (79.6)              0.994

   Hypertension                                     121 (74.7)             45 (76.3)              76 (73.8)              0.726

   COPD                                             128 (79.0)             46 (78.0)              82 (79.6)              0.805

   Diabetes                                         57 (35.2)              20 (33.9)              37 (35.9)              0.795

  Baseline SCr (µmol/L)                             70.0 (60.0--81.3)      70.0 (63.0--82.0)      70.0 (58.0--80.0)      0.327

  Baseline eGFR (mL/min/1.73 m^2^)                  80.1 (72.7--85.9)      78.6 (71.3--85.9)      81.4 (74.1--85.9)      0.233

  Etiology of AKI                                                                                                        

   Sepsis                                           67 (41.4)              25 (42.4)              42 (40.8)              0.843

   Ischemia                                         32 (19.8)              11 (18.6)              21 (20.4)              0.788

   Cardiovascular event                             29 (17.9)              12 (20.3)              17 (16.5)              0.540

   Nephrotoxicity                                   19 (11.7)              8 (13.6)               11 (10.7)              0.584

   Surgery                                          11 (6.8)               2 (3.4)                9 (8.7)                0.328

   Others                                           4 (2.5)                1 (1.7)                3 (2.9)                1.000

  AKI diagnosis time (days)                         2.0 (1.0--5.0)         2.0 (2.0--7.0)         2.0 (1.0--4.0)         0.004

  Parameter at the time of AKI diagnosis                                                                                 

   MAP (mmHg)                                       79±13                  78±12                  79±14                  0.969

   Oliguria                                         16 (9.9)               1 (1.7)                15 (14.6)              0.008

   Dialysis                                         9 (5.6)                3 (5.1)                6 (5.8)                1.000

   MV                                               84 (51.9)              28 (47.5)              56 (54.4)              0.397

  Laboratory results at the time of AKI diagnosis                                                                        

   SCr (µmol/L)                                     138.0 (127.2--160.5)   138.0 (125.2--155.0)   138.0 (128.0--163.0)   0.292

   Peak SCr (µmol/L)                                206.5 (143.3--353.7)   227.0 (150.1--399.3)   183.0 (139.2--341.3)   0.180

   BUN (mmol/L)                                     16.7 (10.7--26.8)      17.1 (10.8--23.4)      16.1 (10.1--27.6)      0.746

   Uric acid (µmol/L)                               399.2 (312.9--506.7)   361.7 (279.2--459.0)   419.0 (335.0--525.2)   0.004

   Prealbumin (g/L)                                 168.0 (125.0--227.0)   163.0 (120.0--209.0)   169.0 (125.0--230.0)   0.614

   Albumin (g/L)                                    33.0±5.2               33.0±5.0               33.1±5.4               0.826

   Kalemia (mmol/L)                                 4.3 (3.8--4.9)         4.1 (3.8--4.7)         4.4 (3.9--4.9)         0.140

   Magnesium (mmol/L)                               0.9 (0.8--1)           0.9 (0.8--1.0)         0.9 (0.8--1.1)         0.943

   Calcium (mmol/L)                                 2.2 (2--2.3)           2.2 (2.1--2.4)         2.2 (2.0--2.3)         0.261

   Phosphate (mmol/L)                               1.3 (1--1.6)           1.2 (0.9--1.5)         1.3 (1.1--1.6)         0.031

   Hemoglobin (g/L)                                 109±23                 106±23                 111±24                 0.382

  AKI stage                                                                                                              0.238

   1                                                37 (22.8)              11 (18.6)              26 (25.2)              

   2                                                41 (25.3)              14 (23.7)              27 (26.2)              

   3                                                84 (51.9)              34 (57.6)              50 (48.5)              

  Mortality rate                                    76 (46.9)              30 (50.8)              46 (44.7)              0.448
  ----------------------------------------------------------------------------------------------------------------------------------

**Notes:** Values are n (%), mean ± SD or median (interquartile range). 1 mmHg =0.133 kPa.

**Abbreviations:** AKI, acute kidney injury; NC, nephrology consultation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MAP, mean aortic pressure (1 mmHg =0.133 kPa); MV, mechanical ventilation; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; SD, standard deviation.

###### 

Associations (with *P*\<0.25) between patients characteristics and delayed NC

  Risk factors         OR      95% CI         *P*-value
  -------------------- ------- -------------- -----------
  AKI diagnosis time   1.269   1.078--1.495   0.004
  Oliguria             0.116   0.014--0.952   0.045
  Uric acid level      0.996   0.994--0.999   0.009
  AKI stage 3          3.365   1.297--8.733   0.013

**Abbreviations:** NC, nephrology consultation; AKI, acute kidney injury; CI, confidence interval; OR, odds ratio.
